|
Real-time Estimate
Cboe BZX
11:59:14 15/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 513.13 USD | -1.23% |
|
-2.40% | +13.86% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 757.44Cr | 893.07Cr | 986.92Cr | 1.1TCr | 1.2TCr | |||||
Total Assets | 1.34TCr | 1.82TCr | 2.27TCr | 2.25TCr | 2.56TCr | |||||
Interest Expense | -6.15Cr | -5.48Cr | -4.41Cr | -3.06Cr | -1.33Cr | |||||
Income Tax Expense | 39Cr | 91Cr | 76Cr | 78Cr | 69Cr | |||||
CAPEX | -24Cr | -20Cr | -20Cr | -30Cr | -44Cr | |||||
EBT | 273.04Cr | 423.24Cr | 437.98Cr | 25Cr | 464.32Cr | |||||
D&A | 13Cr | 15Cr | 18Cr | 18Cr | 18Cr | |||||
Operating Income | 278.21Cr | 430.74Cr | 383.2Cr | -23Cr | 417.33Cr | |||||
Net Income | 234.21Cr | 332.2Cr | 361.96Cr | -54Cr | 395.32Cr |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 528.73Cr | 569.93Cr | 604.04Cr | 668.49Cr | 754.86Cr | |||||
Total Assets | 134.81Cr | 136.55Cr | 135.97Cr | 239.24Cr | 288.84Cr | |||||
Total Assets | 6.09Cr | 7.57Cr | 7.73Cr | 18Cr | 17Cr | |||||
| - | - | - | - | 346.03Cr | ||||||
Europe | 197.29Cr | 270.55Cr | 310.9Cr | 345.39Cr | 346.03Cr | |||||
| - | - | - | - | 99Cr | ||||||
Other | 31Cr | 53Cr | 72Cr | 88Cr | 99Cr | |||||
Total Assets | 1.54Cr | 1.46Cr | 1.59Cr | 1.56Cr | 2.7Cr | |||||
| - | - | - | - | 754.86Cr |
- Stock Market
- Stocks
- VRTX Stock
- Financials Vertex Pharmaceuticals Incorporated
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
